Protalix BioTherapeutics, Inc. has completed a private stock placement
March 2020 — Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Our role in the transaction
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreBischoff & Bischoff has acquired Trendmobil
Bischoff & Bischoff Medizin- und Rehabilitationstechnik GmbH, a portfolio company of Lafayette Mittelstand Capital, has acquired Trendmobil GmbH as a strategic add-on.
Learn moreClinic DPC has been acquired by Meliva
Meliva has acquired 100% of Lithuanian dental care provider Clinic DPC from United Clinics. The transaction further strengthens Meliva’s dental care offering and represents another step in its strategy to expand its presence in the Lithuanian private healthcare market.
Learn more